Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus–pituitary–adrenal system in healthy humans

Neuropsychopharmacology

Volumn 28, Issue 2, 2003, Pages 379-383

  Deuschle, Michael ^a   Lecei, Olivera ^a   Stalla, Günther K ^b   Landgraf, Rainer ^b   Hamann, Bettina ^a   Lederbogen, Florian ^a   Uhr, Manfred ^b   Luppa, Peter ^c   Maras, Athanasios ^a   Colla, Michael ^a,d   Heuser, Isabella ^a,d  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

ACTH; CBG; Cortisol; CRH; CSF; DHEA s; HPA; Plasma; Steroid synthesis; Vasopressin

Indexed keywords

KETOCONAZOLE; STEROID;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BIOSYNTHESIS; BLOOD; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MALE; METABOLISM;

ADULT; AGED; ANALYSIS OF VARIANCE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; KETOCONAZOLE; MALE; PITUITARY-ADRENAL SYSTEM; STEROIDS;

EID: 0037310230     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/sj.npp.1300044     Document Type: Article

References (25)

1. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB (1999). The role of corticotropin-releasing factor in depression and anxietydisorders.J Endocrinol160: 1-12.
2. Deuschle M, Gotthardt U, Schweiger U, Weber B, Körner A, Schmider Jet al(1997a). With aging in humans the activity ofthe hypothalamus-pituitary-adrenal system increases and itsdiurnal amplitude flattens.Life Sci61: 2239-2246.
3. Deuschle M, Schweiger U, Weber B, Gotthardt U, Körner A, Schmider Jet al(1997b). Diurnal activity and pulsatility of thehypothalamus-pituitary-adrenal system in male depressedpatients and healthy controls.J ClinEndocrinolMetab82:234-238.
4. Ebner K, Wotjak CT, Holsboer F, Landgraf R, Engelmann M (1999). Vasopressin released within the septal brain area duringswim stress modulates the behavioural stress response in rats.Eur J Neurosci11: 997-1002.
5. Heuser I, Bissette G, Dettling M, Schweiger U, Gotthardt U, Schmider Jet al(1998). Cerebrospinal fluid concentrations ofcorticotropin-releasing hormone, vasopressin and somatostatinin depressed patients and healthy controls: response toamitriptyline treatment.Depress Anxiety8: 71-79.
6. Heuser I, Schweiger U, Gotthardt U, Schmider J, Lammers C, Dettling Met al(1996). Pituitary-adrenal-system regulation andpsychopathology during amitriptyline treatment in elderlydepressed patients and normal comparison subjects.Am JPsychiatry153: 93-99.
7. Holsboer F (1999). The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depressionand anxiety. JPsychiatr Res33: 181-214.
8. Holsboer F (2000). The corticosteroid receptor hypothesis of depression.Neuropsychopharmacol23: 477-501.
9. Ixart G, Siaud P, Mekaouche M, Barbanel G, Givalois L, Assenmacher I (1994). Short-term but not long-term adrena-lectomy modulates amplitude and frequency of the CRH41episodic release in push-pull cannulated median eminence offree-moving rats.Brain Res658: 185-191.
10. Jenkins JS, Mather HM, Ang V (1980). Vasopressin in human cerebrospinal fluid.J ClinEndocrinolMetab50: 364-367.
11. Kovacs KJ, Foldes A, Sawchenko PE (2000). Glucocorticoid negative feedback selectively targets vasopressin transcriptionin parvocellularneurosecretory neurons.J Neurosci20: 3843-3852.
12. Landgraf R, Neumann I, Holsboer F, Pittman QJ (1995). Interleukin-1ß stimulates both central and peripheral release ofvasopressin and oxytocin in the rat.Eur J Neurosci7: 592-598.
13. Loli P, Berselli ME, Tagliaferri M (1986). Use of ketoconazole in the treatment of Cushing’s syndrome.J ClinEndocrinolMetab63:1365-1371.
14. Ma XM, Aguilera G (1999). Differential regulation of corticotropin-releasing hormone and vasopressin transcription by glucocorti-coids.Endocrinology140: 5642-5650.
15. Raadsheer FC, Hoogendijk WJ, Stam FC, Tilders FJ, Swaab DF (1994). Increased numbers of corticotropin-releasing hormoneexpressing neurons in the hypothalamic paraventricular nucleusof depressed patients.Neuroendocrinology60: 436-444.
16. Schmidt ED, Janszen AW, Binnekade R, Tilders FJ (1997). Transient suppression of resting corticosterone levels induces sustained increase of AVP stores in hypothalamic CRH neurons of rats.J Neuroendocrinol9: 69-77.
17. Schulkin J, Gold PW, McEwen BS (1998). Induction of cortico-tropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety andallostatic load.Psychoneuroendocrinol23: 219-243.
18. Scott LV, Dinan TG (1998). Vasopressin and the regulation of hypothalamic-pituitary-adrenal axis function: implications forthe pahtophysiology of depression.Life Sci62: 1985-1998.
19. Stalla GK, Stalla J, Schopohl J, von Werder K, Miiller OA (1986). Corticotropin-releasing factor in humans.Hormone Res24: 229-245.
20. Stalla GK, Stalla J, von Werder K, Miiller OA, Gerzer R, Holt Vet al(1989). Nitroimidazolederivates inhibit anterior pituitary cellfunction appraently by a direct effect on the catalytic subunit ofthe adenylatecyclase.Endocrinology125: 699-706.
21. Tomori N, Suda T, Tozawa F, Demura H, Shizume K, Mouri T (1983). Immunoreactivecorticotropin-releasing factor concen-trations in cerebropsinal fluid from patients with hypothalamic-pituitary-adrenal disorders.J ClinEndocrinolMetab57: 1305-1307.
22. Wolkowitz OM, Reus VI (1999).Treatment of depression with antiglucocorticoid drugs.Psychosom Med61: 698-711.
23. Wolkowitz OM, Reus VI, Chan Tet al(1999a).Antiglucocorticoid treatment of depression: double-blind ketoconazole.BiolPsy-chiatry45: 1070-1074.
24. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine Let al(1999b). Double-blind treatment of majordepression with dehydroepiandrosterone.Am J Psychiatry156:646-649.
25. Zobel AW, Nickel T, Kunzel HE, Ackl N, Sonntag F, Ising Met al(2000). Effects of the high-affinity corticotropin-releasinghormone receptor 1 antagonist R121919 in major depression:the first 20 patients treated.J Psychiatr Res34: 171-181.